Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 619 results
Found 619 results.

2013

Amorosa VK, Luetkemeyer A, Kang M, et al. "Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial." HIV Clin Trials. 2013;14(6):274-83.
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. "Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES." PLoS ONE. 2013;8(6):e65306.
McLaren PJ, Coulonges C, Ripke S, et al. "Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls." PLoS Pathog.. 2013;9(7):e1003515.
Taiwo B, Matining RM, Zheng L, et al. "Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy." J. Antimicrob. Chemother.. 2013;68(8):1857-61.
Brown TT, Chen Y, Currier JS, et al. "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals." J. Acquir. Immune Defic. Syndr.. 2013;63(3):323-30.
Huang JS, Hughes MD, Riddler SA, Haubrich RH. "Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142." HIV Clin Trials. 2013;14(5):224-34.
Taiwo B, Hunt PW, Gandhi RT, et al. "CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2013;63(1):101-4.
McComsey GA, Daar ES, O'Riordan MA, et al. "Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202." J. Infect. Dis.. 2013;207(4):604-11.
Fiscus SA, Cu-Uvin S, Eshete ATilahun, et al. "Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy." Clin. Infect. Dis.. 2013;57(2):290-7.
Thio CL, Smeaton L, Saulynas M, et al. "Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort." AIDS. 2013;27(2):191-201.
Vardhanabhuti S, Acosta EP, Ribaudo HJ, et al. "Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission." J. Infect. Dis.. 2013;208(4):662-71.
Wohl DA, Kendall MA, Feinberg J, et al. "The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit." PLoS ONE. 2013;8(11):e78676.
Godfrey C, Villa C, Dawson L, Swindells S, Schouten JT. "Controlling healthcare-associated infections in the international research setting." J. Acquir. Immune Defic. Syndr.. 2013;62(4):e115-8.
Zheng L, Rosenkranz SL, Taiwo B, Para MF, Eron JJ, Hughes MD. "The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients." AIDS Res. Hum. Retroviruses. 2013;29(4):652-7.
Zhang X, Tierney C, Albrecht M, et al. "Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146." Ther Drug Monit. 2013;35(2):209-16.
Funderburg NT, Andrade A, Chan ES, et al. "Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine." PLoS ONE. 2013;8(12):e83514.
Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS. "Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults." Lipids Health Dis. 2013;12:23.
Grant PM, Tierney C, Budhathoki C, et al. "Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202." HIV Clin Trials. 2013;14(6):284-91.
Overton ET, Kitch D, Benson CA, et al. "Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death." Clin. Infect. Dis.. 2013;56(10):1471-9.
Harrison T, Miyahara S, Lee A, et al. "Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies." Pain Med. 2013;14(7):1039-47.
Smurzynski M, Wu K, Schouten JT, et al. "Factors associated with remaining on initial randomized efavirenz-containing regimens." AIDS. 2013;27(12):1887-97.
Cespedes MS, Kerns SL, Holzman RS, McLaren PJ, Ostrer H, Aberg JA. "Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268." HIV Clin Trials. 2013;14(6):292-302.
Bartha I, Carlson JM, Brumme CJ, et al. "A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control." Elife. 2013;2:e01123.
McMahon DK, Zheng L, Hitti J, et al. "Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV." Clin. Infect. Dis.. 2013;56(7):1044-51.
Abu-Raddad LJ, Barnabas RV, Janes H, et al. "Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?" AIDS. 2013;27(6):981-9.
Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. "Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment." AIDS. 2013;27(17):2725-34.

Pages